ACTRN12621001406897招募中2 期
Efficacy of Fucoidan for eosinophilic oesophagitis: a phase 2 pilot study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Be aged 18-60 years;
- •-Have EoE diagnosed from oesophageal biopsy, based on eosinophil count greater than15 cells per high powered field;
- •-Be prescribed treatment with steroids and proton pump inhibitor (PPI) therapy for a minimum of 6 weeks as part of the routine clinical management and continue taking the study medication for a further 6 weeks.
排除标准
- •-Report antibiotic, probiotic or symbiotic use in the previous 14 days;
- •-Report gastrointestinal or respiratory disease, autoimmune disease or other diseases, in particular Crohn’s Disease or Ulcerative Colitis;
- •-Return a finding of malignancy on biopsy results post gastroscopy procedure.
- •-Allergic, sensitive or intolerant to (one of) the ingredients of the study product
研究者
相似试验
进行中（未招募）
1 期
study in subjects with Eosinophilic EsophagitisMedDRA version: 20.1 Level: LLT Classification code 10064220 Term: Eosinophilic esophagitis System Organ Class: 100000004856Eosinophilic EsophagitisEUCTR2016-004749-10-BEAdare Pharmaceutical100
进行中（未招募）
1 期
study in subjects with Eosinophilic EsophagitisEosinophilic EsophagitisMedDRA version: 20.0Level: LLTClassification code 10064220Term: Eosinophilic esophagitisSystem Organ Class: 100000013492EUCTR2016-004749-10-ESAdare Pharmaceutical100
进行中（未招募）
1 期
study in subjects with Eosinophilic EsophagitisMedDRA version: 20.1Level: LLTClassification code 10064220Term: Eosinophilic esophagitisSystem Organ Class: 100000004856Eosinophilic EsophagitisEUCTR2016-004749-10-DEAdare Pharmaceutical100
进行中（未招募）
1 期
Treatment of patients with eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II studyEosinphilic EsophagitisEUCTR2012-005842-39-SE-sjukvården, Norra Älvsborgs Länssjukhus60
已完成
2 期
Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)Eosinophilic EsophagitisNCT03191864Adare Pharmaceuticals, Inc.106